Drug Delivery Technology

ISSN: 0975 4415

Peer Review Journal

International Journal of

Drug Delivery Technology

ISSN: 0975 4415

Peer Review Journal

ARCHIVES ~	номе	EDFTORIAL ~	INSTRUCTIONS	CONTACT	SUBMIT MANUSCRIPT	
		Volume 8	, Issue 2; April =	June 2018		
Partition Coefficient and Glutathione Strick Museum County Museum (1)	Penetration o	f Topical Antiaging: Pr	reformulation Study			
Fitria Nugrahaeni, Dewi Melani Hariyadi, N Abstract	oorma Kosita					
2. Formulation and Evaluation of Micros Padhiar J S, Shirolkar S V, Deshkar S S	emulsion Based	d Topical Gel of Carba	mazepine			
Abstract						
Formulation and Frederick - 450 Levil						
Formulation and Evaluation of Galant reddy Srikanth Reddy, Penjuri Subhasi	amine Hydrob h Chandra bose	romide Floating Matri , Vuppula Sruthi, Dam	ix Tablet ineni Saritha			
Abstract						
. Studies on Orally Disintegrating Table	ts Prepared by	Using Natural and Sy	nthetic Superdisintegrant	s ·		
plani Mona, Diwedi Rohini, Bhagwat De Abstract	eepak Prabhak	ar, Pahwa Rakesh				
Preparation and Immunocharacteriza nur M, Bhatia A, Sethi D, Vig K, Kaur G	tion of Probiot	ic DNA Loaded Chitos	san Nanoparticles: An In V	itro and In Vivo Stud	ty	
Abstract						
Skin Penetration of Ubiquinone (Co-Q stiana Erawati M, Widji Soeratri, Noori	10) In Nanoem ma Rosita	ulsion Delivery System	m Using Virgin Cocunut O	il (Vco)		
Abstract						
Design and Evaluation of Ion Activates	d In-Situ Ophth	almic Gel of Brimonid	line Tartarate Using Kanna	Carrageenan		
Design and Evaluation of Ion Activated In-Situ Ophthalmic Gel of Brimonidine Tartarate Using Kappa Carrageenan (azir Ashfaq Ahmed, Divakar Goli Abstract						
Validation of Simvastatin Analysis Mei an Sopyan, Cynthia Jaya, Driyanti Rahay	thods in Huma	n Blood Plasma (In Vita	ro) Using HPLC-UV Detect	or		
Abstract	'u					
Formulation and Evaluation of Chitosa illip Kumar Behera, Kampal Mishra, Padr	n-Polyaniline I molochan Naya	Nanocomposites for C lk	Controlled Release of Antic	ancer Drug Doxoru	ubicin	
Abstract						

10. Characterization and Release of Ibuprofen in Proniosome System (Ibuprofen-Span 60-Cholesterol) Tutiek Purwanti, Dewi Melani Hariyadi, Corry Silvia

Abstract


11. Evaluation of the Physical Stability of Nanostructured Lipid Carrier (NLC) Meloxicam Before and After Strorage 40 Days Rahmi Annisa, Dewi Melani, Esti Hendradi

Abstract

12. The Optimization of Maltodextrin and Arabic Gum in the Microencapsulation of Aqueous Fraction of Clinacanthus nutans Using Simplex Lattice Design Intan Martha Cahyani, Ebta Narasukma Anggraeny, Bekti Nugraheni, Christiana Retnaningsih, V Kristina Ananingsih

Abstract

Impact Factor: 1.529





UGC Approved Journal



This journal is present in UGC approved List of Journals for the purpose of Career Advancement Scheme (CAS) and Direct Recruitment of Teachers and other academic staff as required under the UGC (Minimum Qualifications for Appointment of Teachers and other Academic Staff in Universities and Colleges)

Other Journals published by International Society for Science and Nature



WWW.UPQA.COM

International Journal of Pharmaceutical Quality Assurance



WWW.IJPCR.COM

International Journal of Pharmaceutical and Clinical Research



WWW.UPPR.COM

International Journal of Pharmacognosy and Phytochemical Research



WWW.IJCPR.COM

International Journal of Current Pharmaceutical Review and Research



WWW.IJTPR.COM

International Journal of Toxicological and Pharmacological Research

The publication is licensed under Creative Commons License View Legal Published by Dr. Yashwant Research Labs Pvt. Ltd. on behalf of International Society for Sci

Available online on www.ijddt.com International Journal of Drug Delivery Technology 2018; 8(2); 107-109

ISSN: 0975 4415

Research Article

Evaluation of the Physical Stability of Nanostructured Lipid Carrier (NLC) Meloxicam Before and After Strorage 40 Days

Rahmi Annisa¹, Dewi Melani², Esti Hendradi²

¹Pharmacy Department of Faculty of Medicine and Health Sciences, Universitas Islam Negeri Maulana Malik Ibrahim, Malang, East Java, Indonesia

²Pharmaceutics Department of Faculty of Pharmacy, Universitas Airlangga, Surabaya, East Java, Indonesia.

Received: 26th Oct, 17; Revised: 7th Dec, 17, Accepted: 13th May, 18; Available Online: 25th Jun, 2018

ABSTRACT

Objective: The aims this study was to determine the effect of lipid ratio Monostearin and Miglyol 808 roomates gives the physical stability after storage 40 days. Methods: The NLC making was done by using emulsification method in the formation of NLC meloxicam, 3 different lipid ratios were used, including ratios of 6: 4, 7: 3, 8: 2. Results: NLC meloxicam physical stability of the pH, viscosity, particle size, particle morphology and entrapment efficiency. NLC meloxicam belongs to semisolid preparations with pH value range of 5.72-5.87. Increasing viscosity of NLC system is caused by the increase of solid lipid. The measurement results of particle size of three different lipid formulas indicated that the lipid particle size was <1000 nm. Entrapment efficiency test of all NLC-lipid compositions revealed quite high result (> 80%). Conclusion: The system uses lipid monostearin NLC meloxicam and Miglyol 808 at a ratio of 8: 2 is the most optimal combination shows physical stability after storage 40 days.

Keywords: Nanostructured Lipid Carriers, NLC, Meloxicam, physical stability.

INTRODUCTION

The topical use of meloxicam can be delivery solutions of NSAID drug, directly to the target disease and provide a local effect. This method can also avoid the existence of gastrointestinal side effects because it is not absorbed systemically. Meloxicam has a characteristic which is not soluble in water and has a logP value of 3:42, so in a preparation mostly consisting of water, the solubility of meloxicam would be very small and with the logP values, it means that meloxicam is non-polar. Therefore, the development of this meloxicam topical delivery systems. One of delivery system was selected is Solid Lipid Nanoparticle Solid Lipid Nanoparticle (SLN) is colloidal dispersion in nano size consists of a solid lipid stabilized by surfactants that work in the interface area3. Some advantages of SLN, for instance the ability to protect the active compounds from degradation, controlled release, the ability to load a lipophilic or hydrophilic material, non-toxic and did not irritate3. Limitations of SLN systems included loading capacity of the active ingredient was limited and the expulsion of active ingredient during storage. This was because of the high orderdness of the lattice crystal of solid lipid so that the active ingredient which has been entrapped easily squeezed out of the system. To overcome the limitations of the system SLN, a second-generation

Meloxicam belongs to a group of Non-Steroidal Anti-

Inflammatory Drugs. Meloxicam can be used in

rheumathoid arthritis therapy. However, the use of oral

meloxicam causes gastrointestinal irritation side effects1.

nanoparticle system that is nanostructured lipid carrier (NLC) was developed⁶. NLC are formed with both liquid and solid lipid as a blend mixture in such a ratio that they are solid at room temperature. The active ingridient can be incorporated in particle matrix in a molecular dispersed form or it can be arranged as amorphous cluster⁶.

The NLC manufacturing is done by mixing solid lipid in an amount greater than the liquid lipid. This research used solid lipid (Monostearin), liquid lipid (Miglyol 808) with a ratio of 6: 4, 7: 3, and 8; 2, surfactant (Tween 80) and meloxicam as the active ingredient. Evaluation conducted in this study included physicochemical characteristics after strorage 40 days.

MATERIALS AND METHODS

Materials

The main materials used in this study is meloxicam (Apex Healthcare Limited), Monostearin (Sigma Aldrich), Miglyol 808 (Sigma Aldrich), Tween 80 (PT Croda), pro analysis Ethanol (Merck), Buffer component: KH₂ PO₄ and NaOH pro analysis (Merck). Methods

Preparation NLC System of Meloxicam The Manufacturing of NLC meloxicam

This study used emulsification method (emulsification). Meloxicam-NLC system was made by melting the lipid phase (Monostearin and Miglyol 808) with different lipid ratios (6: 4, 7: 3 and 8: 2), and meloxicam at temperatures of 65 °C. At the same time, a solution of surfactant (Tween-80 and phosphate buffer pH

^{*}Author for Correspondence: estihendradi@yahoo.com

Table 1: The formula of NLC meloxicam.

Ingredient	Function	Concentrate	Concentrate (% -w/ w)		
		range (%)	Formulation I	Formulation II	Formulation III
Meloxicam	Active ingredient		1	1	1
Monostearin	Solid Lipid	6 *	6	7	8
Miglyol 808	Liquid Lipid	3-4 *	4	3	2
Tween 80	Surfactant	1-15 **	5	5	5
Phosphate Buffer			Until 100		
pH 6					

Table 2: The results of pH measurements of the meloxicam NLC system of formula 1, formula 2 and formula 3 on days 1, 20, and 40

Day	Formula	Average pH ± SD
1		
	2 (7: 3)	5.73 ± 0.03
	3 (8: 2)	5.75 ± 0.01
20	1 (6: 4)	5.74 ± 0.04
	2 (7: 3)	5.74 ± 0.04
	3 (8: 2)	5.85 ± 0.03
40	1 (6: 4)	5.83 ± 0.02
	2 (7: 3)	5.85 ± 0.02
	3 (8: 2)	5.87 ± 0.02

 6.0 ± 0.05), was prepared and heated at a temperature of 65 °C Hot surfactant solution then was dispersed into the hot lipid phase by using *ultra-turax* with a speed of 3400 rpm For 30 minutes. The next stage was cooling stage, then it was stirred using a *magnetic stirrer* at 100 rpm until it Reached the temperature of 25 °C. The fixed NLC was measured to Determine the end weight of the NLC^{4,10}. *Evalution of the Physical Stability of NLC Meloxicam* All NLC-MLX were evalution of physical stability before and after storage 40 days in their pH, viscosity, particles

Determination of pH

size, and entrapment efficiency.

Determining pH of each test preparation was done using a pH meter.

Examination of the particle size and size distribution Examination of the particle size consisting of two treatments before and after UVB irradiated for 21 hours. Each sample was diluted to 200 ppm stirring for 3 minutes at 500 rpm. Dilution checked by Delsa Nano Particle Size on the angle of 650 and a temperature of 25° C. Data

Table 4 Measurement results of entrapment efficiency of meloxicam NLC system on days 1, 20, and 40

Day	Formula	Trapping Rate (%) ± SD
1	2 (7: 3)	90.831 ± 0.180
1	3 (8: 2)	94.358 ± 0.109
	1 (6: 4)	88.848 ± 0.522
20	2 (7: 3)	$91,561 \pm 0.412$
	3 (8: 2)	$95,703 \pm 0,510$
	1 (6: 4)	90.996 ± 0.440
40	2 (7: 3)	94.343 ± 0.168
	3 (8: 2)	$95,850 \pm 0.535$

obtained were average particle diameter and Polydispersity Index (PI). All measurement was replicated 3 times. Percentage of Drug Entrapment (Loading capacity)

Drug entrapment efficiency was determined by centrifugation method. It was calculated from the ratio of the medicinal amount in NLC to total added drug amount. Centrifugation was carried out using Hettich Rotofix 32 Centrifuge. About 1 gm of NLC dispersion containing the drug was placed in the centrifuge tube, and sample were centrifuged at 2,500 rpm for 45 minutes. The amount of the free drug in the supernatant was estimated at 362 nm by spectrophotometry.

RESULT AND DISCUSSION

Determination of pH after storage

The pH-measurement results of each of the formulas after storage for 40 days can be seen in Table 2. Based on the results of statistical analysis ANOVA two way on pH testing NLC meloxicam on day 1, day 20 and day 40 showed that there was no difference in pH change significantly during storage, as shown by F value of 0,579

Table 3 The results of particle size measurements and polypspersity index of NLC meloxicam system of formula 1, formula 2, and formula 3 on days 1, 20, and 40

Day	Formula	Particle Size (nm) \pm SD	Polidispersitas Index ± SD
	1 (6:4)	518.9 ± 291.3	0.299 ± 0.236
1	2 (7:3)	472.1 ± 107.1	0.616 ± 0.092
	3 (8:2)	421.9 ± 137.1	421.9 ± 137.1
	1 (6:4)	244.2 ± 23.2	0.438 ± 0.054
20	2 (7:3)	235.4 ± 41.6	0.650 ± 0.251
	3 (8:2)	416.3 ± 143.4	0.495 ± 0.155
	1 (6:4)	333.9 ± 104.0	0.474 ± 0.097
40	2 (7:3)	404.0 ± 240.8	0.565 ± 0.171
	3 (8:2)	610.0 ± 126.6	0.510 ± 0.207

and significant against $\alpha=0.05$ (0.571). The p value for the formula* day is 0.958, it can be concluded that there is no significant pH difference between formula 1, formula 2 and formula 3 on storage time (days). After 40 days of storage it can be concluded that the meloxicam NLC system formed shows the stability of the Meloxicam NLC system in the absence of pH change.

Examination of the particle size and size distribution The result of measuring the particle size of each formula after storage for 40 days can be seen in Table 3. Based on the results of two-way ANOVA statistical analysis particle size measurements obtained F value of 2.861 and significant to $\alpha = 0.05 \, (0.083)$. The p value for the formula* day is 0.390, it can be concluded that there is no significant particle size difference between formula 1, formula 2, and formula 3 on storage time (days). This shows that there is no significant difference in particle size of formula 1, formula 2, and formula 3 during storage from Day 1, 20th, and 40th. After 40 days of storage it can be concluded that the meloxicam NLC system formed shows the stability of the system NLC in the absence of particle size changes.

Measurement of Drug Entrapment efficiency After Storage 40 Days

The measurement of trapping efficiency of each of the formulas after storage for 40 days can be seen in Table 4. Based on the results of two-way ANOVA statistical analysis trapping efficiency measurements obtained F value of 113.06 and significant to $\alpha=0.05$ (0.000), demonstrating the difference between the trapping efficiency of the storage time the 1st, 20th, and to-40. This difference in the efficiency of the trapping is indicated by the increase in trap efficiency after 40 days of storage, indicating that the meloxicam NLC system formed remains stable with no reduction in trap efficiency.

CONCLUSION

NLC system of meloxicam using lipid Monostearin and Miglyol 808 ratio of 8: 2 is the most optimal combination, because it shows physicochemical characteristics according to the criteria of NLC system of meloxicam the post 40-day-storage.

CONFLICT OF INTEREST

I hereby state that no conflict of interest exists between me and the co-author of this manuscript.

REFERENCES

- Bertram, G and Katzung MD., 2009. Basic and Clinical Pharmacology, 11th Ed. United States: McGraw-Hill Companies Ins., pp.817-819
- Cirri, M., Bragagni, M., Mennini, P., 2012. Development of a New Delivery System Consisting "Drug-in Cyclodextrin-in Nanostructured Lipid Carriers" for Ketoprofen Topical Delivery. Eur J of Pharm and Biopharm 80 (1): 46-53.
- 3. Ekambaran, P., Shatali A. A. H., Priyanka K, 2011. Solid Lipid Nanoparticle: A Review. *Scientific Review and Chemical Communication*. Vol.2, pp.80-102
- 4. Khurana, S., Jain, NK, Bedi, PMS, 2013. Development and Characterization of a Novel Controlled Release Drug Delivery System Based on Nanostructured Lipid Carriers Gel for Meloxicam. *Life Sci* 93: 763-772.
- 5. Muller, RH, Mader, K., Gohla, S., 2002. Solid Lipid Nanoparticles for Controlled Drug Delivery a Regiew of the State of the Art. Eur J of Pharm and Biopharm 50: 161-177.
- Pritu Pathak, A.K. Phatak, 2015, Preparation and Evaluation of Nanostructured Lipid Carriers Evaluation of Nanostructured Lipid Carriers of Azelaic Acid in Topical Formulation (Hydrogel), International Journal of Current Pharmaceutical Review and Review and Research; 6(3); 188-194.
- Montenegro, Lucia, 2014, Nanocarriers For Skin Delivery of Cosmetic Antioxidant, *Journal of Pharmacy and Pharmacognosy Research*, Vol 2, No.4, pp 73-92.
- 8. Souto, EB, and Muller, RH, 2007. Lipid Nanoparticles (Solid Lipid Nanoparticles and Nanostructured Lipid Carriers) for Cosmetic, Dermal, and Transdermal Applications. *Drug and Pharm Sci* 166: 213-232.
- Westesen, K., Siekmann, B., 1997. Investigation of the Gel Formation of Solid Lipid Nanoparticles Stabilized Phospholipids. Inter J of Pharm 151: 35-45.
- 10. Yuan, H., Wang LL, Du YZ, You, J., Hu, FQ, Zeng, S., 2007. Preparation and Characteristics of Nanostructured Lipid Carriers for Control Releasing Progesterone by Melt Emulsification. Colloids and Surfaces Biointerfaces 60 (2): 174-179.

International Journal of

Drug Delivery Technology

ISSN: 0975 4415

Peer Review Journal

		Pec	er Review Journal			
ARCHIVES ~	номе	EDITORIAL .	INSTRUCTIONS	CONTACT	SUBMIT MANUSCRIPT	
·						
EDITOR IN CHIEF						
Prof. Dina Nath Mishra Professor and Head of Pharma eutics, Dep. Guru Jambheshwar University of Science and	artment of Pha nd Technology,	INDIA				
Board Members						
Dr. Shailendra K. Singh Guru Jambheshwar University of Science ar						
Dr. Somnath Singh Creighton University,Omaha, USA						
Dr. Parshuram Roy Himachal Institute of pharmaceutical & Res	earch, HP, INDI	IA				
Dr. Tathagata Dutta University of Queensland, Brisbane, AUSTR	ALIA					
Dr. Ashish Suttee Lovely Professional University, Phagwara, IN	NDIA					
Dr. Kalpesh Gaur Geetanjali College of Pharmaceutical Studie	s, Udaipur. IND	DIA				
Dr. Vishal Gupta Director, Research & Developement Covidie	en, USA					
Dr. Chandan M. Thomas Department of Pharmaccutical Sciences, Lai	e Eric College	of Osteopathic Medici	ne and School of Pharmac	y 5000 Lakewood R	anch Blvd, Bradenton, Florida-342	11
Prof. Kamla Pathak Rajiv Academy of Pharmacy, Mathura, INDIA	4					
Prof. V. R. Sinha Panjab University, Chandigarh, INDIA						
Prof. Pramil Tiwari National Institute of Pharamceutical Educati	on and Researc	ch (NIPER), Mohali, IN	DIA			
Prof. Arun Nanda						

Dr. Anil Philip

Prof. O.P.Katare

Dr. Amit Bhatia

Rajiv Academy Academy of Pharamacy, Mathura, INDIA

Faculty of Pharm. Sciences, Maharshi. Dayananad. University, Rohtak, INDIA

Dr. Dinesh Kaushik

Hindu College of Pharamcy, Sonepat, INDIA.

Lovely Professional University, Punjab, INDIA

Panjab University, Chandigarh, INDIA

 ${\bf Dept.\,of\,Pharm.\,Sciences,\,Guru\,Jambheshwar\,University\,of\,Science\,and\,Technology,\,Hisar,\,INDIA}$

Dr. Sanju Nanda
Dept. of Pharm. Sciences, M.D. University, Rohtak, INDIA

Dr. Rakesh P. Patel S.K. Patel College of Pharm. Edu. & Res., Ganpat University, Gujarat, INDIA.

Dr. Bhaskar Mazumder
Dept. of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam, INDIA.

Dr. Kalpana Nagpal Apecjay Satya University, Sohna, Gurgaon, Haryana, INDIA

Submit Manuscript | Contact IJDDT | Join Editorial | Accepted Manuscripts | Home

Impact Factor: 1.529





UGC Approved Journal



This journal is present in UGC approved List of Journals for the purpose of Career Advancement Scheme (CAS) and Direct Recruitment of Teachers and other academic staff as required under the UGC (Minimum Qualifications for Appointment of Teachers and other Academic Staff in Universities and Colleges)

Other Journals published by International Society for Science and Nature



WWW.UPQA.COM

International Journal of Pharmaceutical Quality Assurance



WWW.IJPCR.COM

International Journal of Pharmaceutical and Clinical Research



WWW.UPPR.COM

International Journal of Pharmacognosy and Phytochemical Research



WWW.IJCPR.COM

International Journal of Current Pharmaceutical Review and Research



WWW.UTPR.COM

International Journal of Toxicological and Pharmacological Research

The publication is licensed under Creative Commons License View Legal Published by Dr. Yashwant Research Labs Pvt. Ltd. on behalf of International Society for Sci

International Journal of

Drug Delivery Technology

ISSN: 0975 4415

Peer Review Journal

ARCHIVES > HOME EDITORIAL \ INSTRUCTIONS CONTACT SUBMIT MA	NUSCRIPT
--	----------

INDIA

Published by: DYR Labs Pvt. Ltd. 1/14, Housing Board, devipura, Sikar, India 332001

Branch: Publishers, In-IJDDT 35. Printers Nagar II Sitabari Tonk Road Jaipur, Rajasthan

Email:

For Submission: ijddtjournal@gmail.com

Submit Manuscript | Contact IJDDT | Join Editorial | Accepted Manuscripts | Home

Impact Factor: 1.529





UGC Approved Journal



This journal is present in UGC approved List of Journals for the purpose of Career Advancement Scheme (CAS) and Direct Recruitment of Teachers and other academic staff as required under the UGC (Minimum Qualifications for Appointment of Teachers and other Academic Staff in Universities and Colleges)

Other Journals published by International Society for Science and Nature



WWW.IJPQA.COM

International Journal of Pharmaceutical Quality Assurance



WWW.IJPCR.COM

International Journal of Pharmaceutical and Clinical Research



WWW.UPPR.COM

International Journal of Pharmacognosy and Phytochemical Research



WWW.IJCPR.COM

International Journal of Current Pharmaceutical Review and Research



WWW.IJTPR.COM

International Journal of Toxicological and Pharmacological Research

The publication is licensed under Creative Commons License View Legal Published by Dr. Yashwant Research Labs Pvt. Ltd. on behalf of International Society for Sci

also developed by scimago:





Scimago Journal & Country Rank

Enter Journal Title, ISSN or Publisher Name

Home

Journal Rankings

Country Rankings

Viz Tools

Help

About Us

International Journal of Drug Delivery Technology

Country

Australia - III SIR Ranking of Australia

Pharmacology, Toxicology and Pharmaceutics Pharmaceutical Science

Publisher

International Journal of Drug Delivery Technology

Publication type

Journals

O9754415


Coverage


Join the conversation about this journal


Quartiles Pharmaceutical Science 2012 Q4 Pharmaceutical Science 2013 04 Pharmaceutical Science 2014 Q3 Pharmaceutical Science 2015 Q3 Pharmaceutical Science 2016 03 Pharmaceutical Science 2017 Q3 Pharmaceutical Science 2018 Q3


scientific discussion an average article or the journal is. SJR Year 0.112 2012 2013 0.132 0.159 2014 2015 0.220 2016 0.144 2017 0.123 2018 **Total Cites** Self-Cites


Citations per document

















Dr. Zainab Al-Sharifi 5 days ago

hi sir:

D

I would like to publish my paper in your journal, my name is dr. Zainab Al-Sharifi am from Iraq, Collage of medicine / University of Baghdad

reply

Leave a comment
Name
Email

(will not be published)

0000000000	I'm not a robot	
S	md .	reCAPTCHA
		Privacy - Terms

Submit

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

Developed by:



Powered by:



Follow us on @ScimagoJR

Scimago Lab, Copyright 2007-2019. Data Source: Scopus®

